Syngene International Ltd (SYNGENE)
₹389.30
Mkt cap
₹15,969 Cr
P/E ratio
53.90
P/B
3.24
Div yield
0.32%
ROE
7.78%
ROCE
9.99%
EPS (TTM)
₹7.22
Book value
₹120
52W range
386–671
Sector
Healthcare
Price history
Previous close
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
NSE SYNGENEBSE 539268
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−41.96% from high₹389
₹386+0.88% from low₹671
Current
₹389.30
Prev close
₹395.60
Day
−1.59%
Price performance
1D
−1.92%
1W
−3.18%
1M
−3.89%
3M
−12.67%
6M
−3.17%
1Y
−38.91%
YTD
−40.87%
Financials
Revenue, profit & margin
P/E ratio
53.9×
SYNGENE is 54% above the sector median of 35.0×
SYNGENE53.9×
Sector median35.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 808.10 | 910.10 | 853.50 | 916.90 | 789.70 | 891.00 | 943.70 | 1,018.00 | 874.50 | 910.60 | 917.10 | 1,036.50 | 736.00 | |
| Expenses | 596.20 | 656.00 | 622.00 | 600.00 | 619.90 | 646.20 | 660.10 | 674.40 | 668.10 | 711.10 | 707.90 | 733.10 | 645.20 | |
| Operating Profit | 211.90 | 254.10 | 231.50 | 316.90 | 169.80 | 244.80 | 283.60 | 343.60 | 206.40 | 199.50 | 209.20 | 303.40 | 90.80 | |
| OPM % | 26.22% | 27.92% | 27.12% | 34.56% | 21.50% | 27.47% | 30.05% | 33.75% | 23.60% | 21.91% | 22.81% | 29.27% | 12.34% | |
| Other Income | 23.60 | 14.20 | 25.60 | 16.10 | 50.10 | 16.50 | 18.30 | 18.90 | 17.70 | 15.40 | -55.20 | 16.20 | 11.80 | |
| Interest | 10.50 | 13.00 | 10.80 | 12.90 | 11.70 | 13.10 | 12.40 | 15.90 | 11.60 | 13.20 | 11.90 | 12.10 | 9.60 | |
| Depreciation | 102.10 | 104.60 | 108.10 | 111.10 | 106.90 | 110.90 | 108.70 | 106.10 | 111.20 | 116.50 | 113.70 | 111.50 | 112.20 | |
| Profit before tax | 122.90 | 150.70 | 138.20 | 209.00 | 101.30 | 137.30 | 180.80 | 240.50 | 101.30 | 85.20 | 28.40 | 196.00 | -19.20 | |
| Tax % | 24.00% | 22.69% | 19.32% | 9.76% | 25.27% | 22.72% | 27.49% | 23.78% | 14.41% | 21.24% | 47.18% | 24.54% | -53.12% | |
| Net Profit | 93.40 | 116.50 | 111.50 | 188.60 | 75.70 | 106.10 | 131.10 | 183.30 | 86.70 | 67.10 | 15.00 | 147.90 | -9.00 | |
| EPS in Rs | 2.32 | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.55 | 2.15 | 1.67 | 0.37 | 3.67 | -0.22 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.72% · closed higher next day 18 of last 41
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 18 Oct '23◦ | 26 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24 | 23 Oct '24◦ | 23 Jan '25◦ | 24 Apr '25 | 23 Jul '25 | 5 Nov '25◦ | 22 Jan '26◦ | 29 Apr '26◦ | 29 Jul '26◦ |
| Earnings day | −1.95% | −0.30% | −0.07% | +5.50% | +5.13% | −6.01% | −12.78% | +0.70% | −4.01% | −8.23% | +8.21% | −3.63% |
| +1 day | −2.48% | +4.60% | −0.27% | +4.97% | +4.54% | −9.63% | −15.89% | −0.92% | −4.68% | −17.36% | +10.46% | −6.84% |
| +5 days | −6.18% | +8.20% | −3.67% | +11.10% | +2.80% | −11.85% | −16.18% | +6.81% | +2.41% | −21.07% | +6.00% | −3.50% |
| +15 days | −1.48% | +11.37% | −1.21% | +11.42% | +0.71% | −17.08% | −13.85% | −2.49% | −1.01% | −26.59% | +6.87% | −4.53% |
| +30 days | +0.84% | +1.23% | +1.60% | +20.64% | +5.28% | −19.76% | −13.76% | −4.08% | +1.63% | −30.93% | +4.94% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 1.25 Per Share | 1.25 | 25 Jun '26 | 26 Jun '26 |
Shareholding
as of Jun 202652.59%Promoter
Promoters52.59%0.09
FIIs11.82%2.09
DIIs28.01%1.57
Public7.15%0.46
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SYNGENE | ₹395.60 | 53.92 | 15,969 | 0.32% | −9 | −94.89% | 736 | −15.84% | 9.99% |
| INDGN | ₹601.50 | 34.81 | 14,492 | 0.37% | 116 | −0.17% | 1,063 | +39.73% | 18.82% |
| SUVEN | ₹378.00 | — | 10,681 | 0.00% | −128 | −147.69% | 4 | +90.91% | −79.54% |
| VIMTALABS | ₹635.65 | 35.15 | 2,841 | 0.31% | 21 | +11.38% | 109 | +11.80% | 25.23% |
| FABTECH | ₹150.20 | 13.73 | 668 | 0.40% | 4 | +154.79% | 75 | +10.25% | 13.58% |
| BI | ₹95.85 | 11.34 | 226 | 0.00% | 15 | +473.06% | 226 | +21.20% | 5.56% |
| NOVELIX | ₹76.55 | 60.20 | 218 | 0.00% | 1 | +972.73% | 37 | +65.15% | 9.98% |
| Median: 9 Co. | ₹150.20 | 34.98 | 668 | 0.00% | 1 | +117.42% | 75 | +30.46% | 9.99% |
Filings
Annual reports12
Concall transcripts84
TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptApr 2026PPTApr 2026RECApr 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTSep 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025RECApr 2025PPTMar 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024PPTOct 2024TranscriptJul 2024
Credit ratings6
Announcements5
Grant Of Performance Share Units Under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 ('Plan') 1 Sep - Syngene granted 14,26,061 PSUs to eligible employees on September 1, 2026, at Rs. 10 exercise price.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Aug - Intimation of Schedule of Investor/Analyst Meeting with Goldman Sachs Asia Leaders Conference 2026Announcement under Regulation 30 (LODR)-Acquisition 24 Aug - Syngene to invest Rs 2.52 crore in AMPIN C&I Power Twelve for renewable power procurement.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Aug - Intimation of Investor call schedule with Entrust Family OfficeAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Aug - Intimation of Schedule of Meeting with Analyst/Institutional Investor on August 13, 2026 and August 14, 2026.